Statement on Silicon Valley Bank (SVB)
Melbourne, Australia, 13 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
Commercial Update SCENESSE®
CLINUVEL today published its 2022 status report on the commercial distribution of...
Read More
Relief from Quarterly Reporting
Melbourne, Australia, 2 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
Proposed issue of Securities
Melbourne, Australia, 28 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
Global SCENESSE® demand drives increased CLINUVEL revenues, earnings
Melbourne, Australia, 24 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
Appendix 4D Half Yearly Report
Melbourne, Australia, 24 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
Appendix 4C & Activity Report
Melbourne, Australia, 31 January 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More
Notification of cessation of securities
Melbourne, Australia, 21 December 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
Appendix 3Y - Change of Director’s Interest Notice
Melbourne, Australia, 07 November 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
Appendix 4C & Activity Report
CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4C – Quarterly Cashflow Report...
Read More
Results of Annual General Meeting 2022
In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations...
Read More
CLINUVEL confirms AGM date
CLINUVEL confirms the date for the Company’s 2022 Annual General Meeting.
Read More
CLINUVEL Investor Webinar Financial Results Year Ended 30 June 2022
CLINUVEL PHARMACEUTICALS LTD hosted an investor webinar on the financial results for...
Read More